The relationship between cardiovascular disease and diabetic peripheral neuropathy is mainly sustained by data retrieved from cross-sectional studies focused on cardiovascular risk factors. We aimed to assess the presence of cardiovascular disease as a risk factor for developing diabetic peripheral neuropathy in a type 2 diabetes mellitus population.
Method:
A 10-year prospective, primary care, multicentre study in a randomly selected cohort. Cardiovascular disease presence included stroke, coronary artery disease and/or peripheral ischaemia. Diabetic peripheral neuropathy diagnosis was based on clinical neurological examination as well as the neuropathy symptoms score and nerve conduction studies.
Results:
Three hundred and ten (N=310) patients were initially recruited. Two-hundred and sixty seven (N=267) patients were included in the study. Diabetic peripheral neuropathy cumulative incidence was 18.3% (95% confidence intervals 14.1–23.4; N=49). Diabetic peripheral neuropathy development was significantly more frequent in participants presenting with cardiovascular disease at baseline (P=0.01). In the final logistic regression analysis, the presence of cardiovascular disease remained associated with an increased risk for diabetic peripheral neuropathy (odds ratio 2.32, 95% confidence intervals 1.03–5.22) in addition to diabetes duration and low density lipoprotein-cholesterol levels.
Conclusions:
In our series, type 2 diabetes mellitus patients with cardiovascular disease at baseline present with an increased risk of developing diabetic peripheral neuropathy at 10 years of follow-up. Our results suggest that measures aimed at the prevention, control and treatment of cardiovascular disease can also help prevent diabetic peripheral neuropathy development.
HolzerSECamerotaAMartensL. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther1998; 20: 169–181.
2.
MayfieldJAReiberGESandersLJ. Preventive foot care in people with diabetes. Diabetes Care1998; 21: 2161–2177.
3.
BoultonAJVinikAIArezzoJC. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care2005; 28: 956–962.
4.
KärvestedtLMårtenssonEGrillV. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care2009; 32: 317–322.
5.
GordoisAScuffhamPShearerA. The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care2003; 26: 1790–1795.
6.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care2008; 31: 596–615.
7.
BoultonAJVileikyteL. The diabetic foot: the scope of the problem. J Fam Pract2000; 49 (11 Suppl.): S3–S8.
HaffnerSMLehtoSRönnemaaT. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 23; 339 (4): 229–234.
10.
LawlorDAFraserAEbrahimS. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med2007; 4: e263.
11.
MazzoneTMeyerPMKondosGT. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes2007; 56: 849–855.
12.
GaedePVedelPLarsenN. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med2003; 348: 383–393.
13.
Pop-BusuiREvansGWGersteinHC. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010; 33:1578–1584.
14.
HsuWCChiuSYYenAM. Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol2012; 19:1192–1198.
15.
ElliottJTesfayeSChaturvediN. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care2009; 32:1896–1900.
16.
ChungJOChoDHChungDJ. Association between diabetic polyneuropathy and cardiovascular complications in type 2 diabetic patients. Diabetes Metab J2011; 35: 390–396.
17.
BrownriggJRde LusignanSMcGovernA. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart2014; 100(23): 1837–43.
18.
JuradoJYbarraJSolanasP. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract2009; 21: 140–148.
19.
Diagnosis and classification of diabetes mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization, 1999.
20.
JuradoJYbarraJRomeoJH. Clinical screening and diagnosis of diabetic polyneuropathy: the North Catalonia Diabetes Study. Eur J Clin Invest2009; 39: 183–189.
21.
JuradoJYbarraJRomeoJH. Angiotensin-converting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study. J Diabetes Complications2012; 26: 77–82.
22.
TesfayeSChaturvediNEatonSE. for the EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med2005; 352: 341–350.
23.
SibalLLawHNGebbieJ. Cardiovascular risk factors predicting the distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci2006; 1084: 304–318.
24.
SimaAAKamiyaH. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci2006; 1084: 1235–1249.
25.
OwolabiMOIpadeolaAAdeleyeJO. Aggregate cardiovascular risk is a stronger statistical correlate of clinically evident diabetic peripheral neuropathy than HbA1c alone. J Natl Med Assoc2010; 102: 707–712.
26.
OwolabiMOIpadeolaA. Total vascular risk as a strong correlate of severity of diabetic peripheral neuropathy in Nigerian Africans. Ethn Dis2012; 22: 106–112.
27.
MaserREMitchellBDVinikAI. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care2003; 26: 1895–1901.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–853.
34.
CallaghanBCChengHTStablesCL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol2012; 11: 521–534.
35.
JangEHParkYMHurJ. Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes. Diabet Med2013; 30: 694–701.
36.
WigginTDSullivanKAPop-BusuiR. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes2009; 58: 1634–1640.
37.
PadillaADescorbethMAlmeydaAL. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res2011; 1370: 64–79.
38.
McCallKDHollidayDDickersonE. Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol2010; 207: 343–353.
39.
VincentAMHayesJMMcLeanLL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes2009; 58: 2376–2385.
JangERLeeCS. 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-kappa B and Akt pathways. Neurochem Int2011; 58: 52–59.
42.
TothPPSimkoRJPalliSR. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol2012; 14: 109.
43.
BoussageonRSupperIErpeldingerS. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Med Res Methodol2013; 30: 107.
44.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317: 703–713.
45.
KeechACMitchellPSummanenPA. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet2007; 370: 1687–1697.
46.
American Diabetes Association. American Academy of Neurology Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care1988; 11: 592–597.
47.
TesfayeSBoultonAJDyckPJ. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010; 33: 2285–2293.
